#10 ImClone
180 Varick St.
New York, NY 10014
Tel: (212) 645-1405
Fax: (212) 645-2054
www.imclone.com
| Headcount |
991 |
|
| Year Established |
1984 |
|
| Biopharma Revenues |
$221 |
+8% |
| Total Revenues |
$384 |
-1% |
| Net Income |
$86 |
-25% |
| R&D Budget |
$99 |
+19% |
| Drugs Approved/Launched |
| Drug |
Indication |
| erbitux |
head and neck cancer
|
| Drugs in Phase IIb and Beyond |
| Drug |
Indication
|
| erbitux |
earlier stage colorectal cancer, non-small cell lung cancer, pancreatic cancer
|
| cdp-791 |
solid and liquid tumors
|
Early Research Projects
|
| Drug |
Indication |
imc-11F8
|
solid tumors |
| imc-A12 |
solid tumors |
| imc-18F1 |
breast cancer, CRC |
| imc-3G3 |
prostate, breast, ovarian cancer |
imc-1121b
|
solid and liquid tumors |
Top Selling Drugs
|
| Drug |
Indication
|
Sales
|
(+/-%)
|
| erbitux |
cancer |
$221 |
+8% |
Account for 100% of total biopharma sales, same as in 2004.
|
